Seeking Alpha

Athersys (ATHX +6.4%) gets a boost today, possibly from an upbeat Seeking Alpha piece that touts...

Athersys (ATHX +6.4%) gets a boost today, possibly from an upbeat Seeking Alpha piece that touts its strong pipeline. ATHX is a clinical stage biopharmaceutical company with a number of potential catalysts in its portfolio. Its most advanced programs are in the area of regenerative medicine using its stem cell therapy called MultiStem for the treatment of ischemic stroke. StemCells (STEM -2.3%) slips, possibly on the same article, which says it's in pre-clinical trials for the same indication, but its product isn't as advanced as that of ATHX.
From other sites
Comments (1)
  • Trainer
    , contributor
    Comments (136) | Send Message
     
    Suspect ATHX is a gem that has everything in place except the savvy PR required to inform the street of its potential. Perhaps a favorable article after months of silence woke a few investors up. Good to see.
    22 Jan 2013, 04:23 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector